

Pharmacological Insights and Clinical Strategies in the Treatment of Iron and Vitamin B12 Deficiency Anemia

Saravanan Madhumitha¹; Murugavel Elakkkiya²; Cathalin Salaman³;
Anandhavolu Sorna⁴; Shafana Farveen⁵; Momunava A.A.⁶; Bhakhtierova M.B.⁷

^{1;2;3;4;5;6;7}International Medical Faculty, Osh State University

⁷(<https://orcid.org/0009-0003-8030-656X>)

Publication Date: 2025/11/01

Abstract: Iron deficiency anemia (IDA) and vitamin B12 deficiency anemia are two of the most common types of nutritional anemia that affect people of all ages all over the world. Iron deficiency anemia and vitamin B12 deficiency anemia, if left and examined or untreated until late in the course, may result in fatigue, weakness, occasionally neurologic abnormalities. Early diagnosis and treatment must be made easy in order to ensure improved patient wellbeing and to prevent complications. The clinical and pharmacological treatment of Iron deficiency anemia and B12 deficiency anemia is presented in this article, with a focus on administration of different iron preparations like ionic(divalent) and non-ionic (trivalent). Vitamin B12 replacement therapy, administration, administration doses, and monitoring for safety and efficacy are presented. The aim is to offer evidence based recommendations for selecting the optimum treatment for a given patient.

Keywords: Iron Deficiency Anemia, Vitamin B12 Deficiency Anemia, Divalent and Trivalent Iron, Pharmacological Management, Treatment Safety and Effectiveness.

How to Cite: Saravanan Madhumitha; Murugavel Elakkkiya; Cathalin Salaman; Anandhavolu Sorna; Shafana Farveen; Momunava A.A.; Bhakhtierova M.B. (2025) Pharmacological Insights and Clinical Strategies in the Treatment of Iron and Vitamin B12 Deficiency Anemia. *International Journal of Innovative Science and Research Technology*, 10(10), 2004-2007. <https://doi.org/10.38124/ijisrt/25oct1233>

I. INTRODUCTION

Anemia is a pathological condition where the blood in the body has fewer hemoglobin or red cells than when it is a healthy, minimizing the ability of the blood to carry oxygen to the rest of the body of all anemia types, iron deficiency anemia and vitamin B12 deficiency anemia are the more common dietary anemia. Iron deficiency anemia (IDA) most often results from dietary deficiency of iron, on going blood loss, or altered absorption from the Gastrointestinal tract (GI). Deficiency anemia of vitamin B12 is caused by insufficient intake, malabsorption or autoimmune illnesses that disrupt absorption of B12. Both types of anemia can be disasters to a person's energy, mental status and overall quality of life. Treatment is based on identification of the pathogenesis, choice of the correct regimen of treatment and response follow up . Pharmacologic treatment is done by administration of the ionic (divalent) and non ionic (trivalent) forms of iron and Vitamin B12 administration. This review attempts to provide suggestions about how to select the most suitable therapy, how to dose , and how to assess the effectiveness and safety of such treatment in the clinic.

➤ Objectives

- To study the clinical and pharmacological aspects of iron deficiency and vitamin B12 deficiency anemia.
- To interrelate efficacy, dosage, and safety of ionic (ferrous) and non-ionic (ferric) iron compounds.
- To provide rational guidelines for selection and evaluation of iron and vitamin B12 treatment in anemia therapy.

II. METHOD OF STUDY

A. Iron Deficiency Anemia (IDA)

➤ Pathophysiology

Iron is essential for hemoglobin formation and manufacture of normal red cells. Reduced size red cells containing less hemoglobin occur when the body is not receiving enough iron to meet its needs, and this leads to microcytic, hypochromic anemia. The causes are as follows:

- *Major Reasons are:*

- ✓ Chronic blood loss (gastrointestinal bleeding, heavy menstruation)
- ✓ Inadequate dietary intake of iron
- ✓ Increased requirement (pregnancy, growth)
- ✓ Malabsorption (celiac disease, intestinal disorders)

- *Clinical Features*

- Fatigue, pallor, weakness.
- Glossitis, angular cheilitis
- Koilonychia (spoon-shaped nails)
- Cognitive and developmental delay (in children)

- *Diagnostic Evaluation*

- *Diagnosis Involves:*

- ✓ Low serum ferritin (<15 ng/ml)
- ✓ Reduced serum iron and transferrin saturation
- ✓ Raised total iron-binding capacity (TIBC)
- ✓ Microcytic, hypochromic RBCs on peripheral smear

B. Vitamin B12 Deficiency Anemia

- *Pathophysiology*

Vitamin B12 (Cobalamin) is required for DNA synthesis and neurological function. Its deficiency causes megaloblastic anemia with nuclear maturation failure of RBC precursors. Causes which includes pernicious anemia, malabsorption (eg, Crohn disease), gastric resection, and vegetarian diet.

- *Clinical Features*

- Pallor, glossitis
- Paresthesia, neuropathy
- Memory impairment
- Macrocytosis on peripheral smear

- *Pharmacological Management*

- Cyanocobalamin (Vitamin B12): IM 1000 µg daily for 1 week, weekly for 1 month, then monthly maintenance.
- Hydroxocobalamin: IM 1000 µg every 2-3 months (longer acting is preferred). Maintenance is with oral and intranasal preparations.

- *Pharmacological Management of Iron Deficiency Anemia*

Table 1 Classification and Clinical use of Iron Preparations

Type	Examples	Iron form	Route	Main use
Ionic (Ferrous) salts	Ferrous sulfate, ferrous fumarate, ferrous gluconate	Fe ²⁺	Oral	First-line for mild to moderate anemia
Non- ionic (Ferric) complexes	Iron(III)- hydroxide polymaltose, iron sucrose, ferric carboxymaltose, iron-protein succinylate	Fe ³⁺	Oral or IV	Used when ferrous salts are not tolerated or when rapid correction is needed

- *Ionic (Ferrous) Iron Preparations*

- Ferrous salts are well absorbed and therefore most often used. Ferrous (Fe²⁺) Iron is absorbed primarily in the duodenum.

- *Examples of Common Preparations and Dosages:*

- ✓ Ferrous sulfate- 200 mg tablet containing 60 mg elemental iron three times a day.
- ✓ Ferrous fumarate- 300 mg twice a day.
- ✓ Ferrous gluconate- 325 mg three times a day.
- ✓ Benefits: Low cost, effective in the majority of patients.
- ✓ Drawbacks: Gastrointestinal side effects like nausea, constipation, and black stools. These are avoided by taking the tablet postprandial or switching to another preparation.

- *Non-Ionic (Ferric) Iron Preparations*

- Newer compounds with gradual release of iron and greater tolerance.

- *Iron Polymaltose Complex*

- ✓ Binds ferric hydroxide to a carbohydrate (polymaltose).
- ✓ Iron is released gradually, improving absorption and reducing side effects.
- ✓ Dosage: 100-200 mg elemental iron daily.
- ✓ Safe in children and pregnant woman.

- *Iron Sucrose Complex*

- ✓ Iron(III)- hydroxide is bonded to sucrose.
- ✓ Given intravenously in 200mg doses every 1-2 weeks.
- ✓ Frequently utilized in renal disease or oral iron intolerance patients.
- ✓ Fewer allergic reactions compared to older IV products.

- *Iron Protein Succinylate*

- ✓ Combines ferric iron with a protein complex.
- ✓ Provides slow and persistent absorption with good gastric tolerance.

• *Ferric Carboxymaltose*

- ✓ More recent IV preparation for infusion of large single doses (up to 1000 mg).
- ✓ Useful for rapid correction in severe anemia or during pregnancy.
- ✓ Low risk of hypersensitivity reaction.

III. EVALUATION OF EFFECTIVENESS AND SAFETY

➤ *Effectiveness*

- A rise in hemoglobin by about 1g/dL within 2-3 weeks of treatment indicates a good response.
- Reticulocyte count increases within 7-10 days.
- Ferritin levels become normal within 2-3 months.

➤ *Safety*

Table 2 Safety Profile and Adverse Effects of Iron Preparations

Preparation	Common Side Effects	Safety Tips
Ferrous salts	Constipation, nausea, metallic taste	Take with meals or in smaller doses
Polymaltose complex	Mild GI discomfort (rare)	Safe in pregnancy and children
Iron sucrose/ carboxymaltose(IV)	Mild hypertension, injection site pain	No test dose needed, monitor infusion

➤ *Combined Therapy*

In some patients, especially those who are elderly or malnourished, both iron and vitamin B12 deficiencies may occur together, leading to mixed anemia. In such cases, combined supplementation of iron and vitamin B12 is recommended, as it helps correct both the microcytic (iron deficiency) and macrocytic (vitamin B12 deficiency) components of anemia. This combined therapy supports normal red blood cell formation, enhances hematopoiesis, and promotes faster and more complete patient recovery.

IV. SUGGESTION

Anemic patient's should always be subjected to proper diagnostic testing to ascertain the specific cause and type before any therapy can be initiated. Oral ferrous salts can be used as the first line of initial iron deficiency but if intolerance or failure to respond by patients is observed, ferric or injectable iron preparations should be adopted. Hemoglobin and ferritin levels should be checked regularly to evaluate the effectiveness and safety of treatment. In malnourished or elderly patients, simultaneous supplementation of both iron and vitamin B12 can provide faster recovery and better correction of anemia. Awareness of proper nutrition and early detection of anemia can also reduce its occurrence and prevent additional complications.

V. CONCLUSION

Two of the most common and treatable forms of anemia are vitamin B12 deficiency anemia and iron deficiency anemia. A thorough understanding of their pathogenesis, clinical course, and pharmacologic treatment is essential for effective therapy. Ferrous salts remain the norm for iron deficiency, with more recently developed ferric complexes offering Enhanced safety and tolerability. Vitamin B12 therapy, especially parenteral administration, quickly and spares neurological damage. In combined deficiency states, concomitant treatment with iron and vitamin B12 facilitates more rapid correction and overall improved recovery. Rational choice of drugs, proper dosing, and serial monitoring are the keys to successful and safe results.

REFERENCES

- [1]. Alexander K.C. leung, Joseph M. Lam, et Al. Iron deficiency anemia: An updated review. *Current pediatr Rev.* Aug,2023,20(3): P339-356. <https://doi.org/10.2174/1573396320666230727102042>
- [2]. Aditi Kumar, Esha Sharma, et Al. Iron deficiency anemia: pathophysiology, assessment, practical management. *BMJ open Gastroenterol.* Jan,2022,9(1): e000759. <https://doi.org/10.1136/bmjgast-2021-000759>
- [3]. Shikha Bathla, Shalini Arora. Prevalence and approaches to manage iron deficiency anemia (IDA). *Crit Rev Food Sci Nutr.* Jun,2021, 62(32): P8815-8828. <https://doi.org/10.1080/10408398.2021.1935442>
- [4]. Anthony Lopez, Prof Patrice Cacoub, et Al. Iron deficiency anemia. *The Lancet.* Feb, 2016,387(10021): P907-916. [https://doi.org/10.1016/s0140-6736\(15\)60865-0](https://doi.org/10.1016/s0140-6736(15)60865-0)
- [5]. Maria Domenica cappellini, Josep comin-colet, et Al. Iron deficiency across chronic inflammatory conditions: International expert opinions on definition, diagnosis, and management. *Am J hematol.* Jul,2017, 92(10): P1068-1078. <https://doi.org/10.1002/ajh.24820>
- [6]. Santiago Garcia-Lopez, Judith Millastre Bocos, et Al. High-dose intravenous treatment in iron deficiency anemia in Inflammatory bowel disease: Early efficacy and impact on quality of life. *Blood Transfus.* May,2016, 14(2): P199-205. <https://doi.org/10.2450/2016.0246-15>
- [7]. Kristine Michelle Jimenez, Christoph Gasche. Management of Iron deficiency anaemia in Inflammatory bowel disease. *Acta haematol.* Apr,2019, 142(1): P32-36. <https://doi.org/10.1159/000496728>
- [8]. Christoph Gasche, Tariq Ahmad, et Al. Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: Results from a Phase-3 Clinical Trial Program. *Inflammatory*

- bowel disease. Mar, 2015, 21(3): P579-588.
<https://doi.org/10.1097/mib.0000000000000314>
- [9]. Benjamin Elsrott, Lubna Khan, et Al. The role of iron depletion in adult iron deficiency anemia and other diseases. Eur J Haematol. Mar,2020, 104(3): P153-161. <https://doi.org/10.1111/ejh.13345>
- [10]. Thomas G. DeLoughery, Christian S. Jackson, et Al. AGA Clinical Practice Update on Management of Iron Deficiency Anemia: Expert Review. Clin Gastroenterol Hepatol. Aug,2024, 22(8): P1575-1583. <https://doi.org/10.1016/j.cgh.2024.03.046>
- [11]. Jean – Louis Guéant, Rosa-Maria Guéant-Rodriguez, et Al. Vitamin B12 absorption and malabsorption. Vitamin Horm. Mar,2022, 119: P241-274. <https://doi.org/10.1016/bs.vh.2022.01.016>
- [12]. Ch S Pavlov, I V damulin, et Al. Neurological disorders in Vitamin B12 deficiency. Ter Arkh. May,2019, 91(4): P122-129. <https://doi.org/10.26442/00403660.2019.04.000116>
- [13]. Alexander J Layden, Kristof Täse, et Al. Neglected tropical diseases and vitamin B12: A review of the current evidence. Trans R soc Trop Med Hyg. Oct,2018,112(10): P423-435. <https://doi.org/10.1093/trstmh/try078>
- [14]. Gabriele Röhrig, Ines Gütgemann, et Al. [Clinical hematological symptoms of vitamin B12 deficiency in old age : Summarized overview of this year's symposium of the Working Group "Anemia in the Aged" on the occasion of the annual conference of the German Geriatric Society (DGG) in Frankfurt]. Z Gerontol Geriatr. Jun,2018, 51(4): P446-452. <https://doi.org/10.1007/s00391-018-1410-z>
- [15]. Robert C. Langan, Andrew J. Goodbred. Vitamin B12 Deficiency: Recognition and management. Am fam physician. Sep,2017,96(6): P384-389. PMID: 28925645
- [16]. Robert C langan, Kimberly J Zawistoski. Update on Vitamin B12 deficiency. Am fam physician. Jun,2011,83(12): P1425-1430. PMID: 21671542